The global companion diagnostics market is projected to grow at a robust CAGR of approximately 13% through 2031. This growth is driven by the increasing demand for personalized medicine, continuous ...

Peer-reviewed publication in “The Oncologist” is now available onlineInvestigational same-day dosing of Rolvedon demonstrated a clinical response and adverse event profile similar to next-day ...

Q4 2025 preliminary net product revenues from global sales of IMCIVREE® (setmelanotide) of approximately $57 million for the ...

Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three ...

HERCESSI(TM) becomes one of two trastuzumab biosimilars on preferred formulary placement, expanding patient access to more affordable HER2-targeted oncology therapies RALEIGH, N.C., Jan. 5, 2026 ...

Q4 2025 preliminary net product revenues from global sales of IMCIVREE- (setmelanotide) of approximately $57 million for the fourth quarter of 2025, an 11% increase over Q3 2025 -- -- FY 2025 prelimin ...

Sachs Associates 9th Annual Neuroscience Innovation Forum Company Presentation Presenter: Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals Date: Sunday, January 11, ...

Fresenius Kabi, an Operating Company of Fresenius, and a leading provider of essential medicines and medical technologies, ...

Preliminary Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth ...

Detailed price information for Ascendis Pharma ADR (ASND-Q) from The Globe and Mail including charting and trades.

Telitacicept, a dual inhibitor of the cytokines B-lymphocyte stimulator and a proliferation-inducing ligand, showed efficacy ...

We are fighting for transparency, accountable science, and for the rights of the common people to receive informed consent.